Ketamine, which has demonstrated efficacy in cases of chronic, treatment-resistant depression, exhibits a broad spectrum of anti-inflammatory effects (e.g., TNFα and IL-6 inhibition) in both clinical and preclinical studies (Murrough et al., 2013; Tan et al., 2017; Chen et al., 2018). Here, TNF is linked to major depressive disorder.